Foundry Partners’s Select Medical SEM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | $4.61M | Buy |
276,156
+15,427
| +6% | +$284K | 0.24% | 134 |
|
|
2024
Q4 | $4.91M | Sell |
260,729
-195,587
| -43% | -$3.77M | 0.25% | 137 |
|
|
2024
Q3 | $8.57M | Buy |
456,316
+15,889
| +4% | +$304K | 0.42% | 69 |
|
|
2024
Q2 | $8.32M | Sell |
440,427
-179,154
| -29% | -$3.06M | 0.45% | 63 |
|
|
2024
Q1 | $10.1M | Buy |
619,581
+54,076
| +10% | +$792K | 0.54% | 48 |
|
|
2023
Q4 | $7.16M | Buy |
565,505
+48,733
| +9% | +$615K | 0.43% | 66 |
|
|
2023
Q3 | $7.04M | Buy |
516,772
+124,644
| +32% | +$1.92M | 0.44% | 68 |
|
|
2023
Q2 | $6.73M | Buy |
392,128
+50,643
| +15% | +$785K | 0.41% | 66 |
|
|
2023
Q1 | $4.76M | Buy |
341,485
+17,197
| +5% | +$253K | 0.3% | 102 |
|
|
2022
Q4 | $4.34M | Buy |
324,288
+40,808
| +14% | +$527K | 0.24% | 115 |
|
|
2022
Q3 | $3.38M | Buy |
283,480
+36,742
| +15% | +$522K | 0.21% | 126 |
|
|
2022
Q2 | $3.14M | Buy |
246,738
+26,973
| +12% | +$346K | 0.19% | 146 |
|
|
2022
Q1 | $2.84M | Sell |
219,765
-480,016
| -69% | -$6.34M | 0.15% | 191 |
|
|
2021
Q4 | $11.1M | Sell |
699,781
-61,643
| -8% | -$1.05M | 0.39% | 103 |
|
|
2021
Q3 | $14.8M | Buy |
761,424
+151,747
| +25% | +$3.01M | 0.53% | 70 |
|
|
2021
Q2 | $13.9M | Sell |
609,677
-212,507
| -26% | -$4.41M | 0.48% | 77 |
|
|
2021
Q1 | $15.1M | Sell |
822,184
-252,503
| -23% | -$4.14M | 0.5% | 67 |
|
|
2020
Q4 | $16M | Buy |
1,074,687
+4,798
| +0.4% | +$62.6K | 0.63% | 46 |
|
|
2020
Q3 | $12M | Sell |
1,069,889
-12,333
| -1% | -$121K | 0.58% | 53 |
|
|
2020
Q2 | $8.59M | Buy |
1,082,222
+55,212
| +5% | +$457K | 0.42% | 83 |
|
|
2020
Q1 | $8.3M | Buy |
1,027,010
+170,403
| +20% | +$2.02M | 0.47% | 69 |
|
|
2019
Q4 | $10.8M | Sell |
856,607
-572,647
| -40% | -$6.17M | 0.41% | 90 |
|
|
2019
Q3 | $12.8M | Buy |
1,429,254
+151,378
| +12% | +$1.32M | 0.53% | 62 |
|
|
2019
Q2 | $10.9M | Buy |
1,277,876
+126,323
| +11% | +$998K | 0.43% | 78 |
|
|
2019
Q1 | $8.74M | Buy |
1,151,553
+94,826
| +9% | +$762K | 0.35% | 98 |
|
|
2018
Q4 | $8.74M | Buy |
1,056,727
+124,742
| +13% | +$1.19M | 0.39% | 85 |
|
|
2018
Q3 | $9.24M | Sell |
931,985
-518,885
| -36% | -$5.37M | 0.35% | 96 |
|
|
2018
Q2 | $14.2M | Buy |
1,450,870
+127,800
| +10% | +$1.25M | 0.58% | 39 |
|
|
2018
Q1 | $12.3M | Buy |
1,323,070
+81,920
| +7% | +$780K | 0.52% | 56 |
|
|
2017
Q4 | $11.8M | Buy |
1,241,150
+39,520
| +3% | +$378K | 0.49% | 66 |
|
|
2017
Q3 | $12.4M | Sell |
1,201,630
-253,416
| -17% | -$2.34M | 0.5% | 56 |
|
|
2017
Q2 | $12M | Buy |
1,455,046
+56,962
| +4% | +$427K | 0.49% | 62 |
|
|
2017
Q1 | $10.1M | Buy |
1,398,084
+170,212
| +14% | +$1.23M | 0.42% | 77 |
|
|
2016
Q4 | $8.77M | Sell |
1,227,872
-430,230
| -26% | -$2.99M | 0.38% | 84 |
|
|
2016
Q3 | $12.1M | Buy |
1,658,102
+63,659
| +4% | +$405K | 0.64% | 37 |
|
|
2016
Q2 | $9.34M | Buy |
+1,594,443
| New | +$10.6M | 0.53% | 60 |
|
Other funds holding SEM
HRCM
Foundry Partners's SEM Position: Q1 2025 in Review
Foundry Partners increased its Select Medical (SEM) stake by 5.9% in Q1 2025, buying an estimated $284K and bringing the position to 276,156 shares worth $4.61M. The position accounts for 0.24% of the portfolio, ranked #134.
Foundry Partners first reported a position in SEM in Q2 2016 and has held it in 36 quarters since. The position peaked at $16M in Q4 2020. 274 funds tracked by Wall St. Rank hold SEM as of Q1 2025.
- Foundry Partners held 276,156 shares of Select Medical worth $4.61M as of Q1 2025.
- Foundry Partners bought 15,427 Select Medical shares in Q1 2025, an estimated $284K.
- Select Medical made up 0.24% of Foundry Partners's portfolio in Q1 2025, its #134 holding.
- Foundry Partners first reported a position in Select Medical in Q2 2016 and has held it in 36 quarters since.
- Foundry Partners's Select Medical position peaked at $16M in Q4 2020.
- 274 funds tracked by Wall St. Rank held Select Medical as of Q1 2025.
Based on Foundry Partners's 13F filing for Q1 2025, filed 5 May 2025.